Biotech Values

[Biowatch]

Re: Piper C L U S I O N Do you have a link for that?

Thanks in advance.

2. Heart failure explodes on the biopharma scene with gene therapy success

Who is working on it? What projects are in the works? What are they targeting?

4. Failed trials get approved, starting with BMRN's drisapersen

Even if drisapersen gets approved, why can this be generalized to other failed trials?
Or do they mean Duchenne's Muscular Dystrophy only?
http://www.fiercebiotech.com/story/prosensa-gets-fda-green-light-its-once-failed-dmd-drug/2014-06-03

8. PD1 antibodies start to look like a thing of the past

I wouldn't write off PD1 antibodies yet. We don't have CART (Chimeric Antigen Receptor T-cells) available for all cancers.
http://www.medscape.com/viewarticle/810688_3

10. A biosimilar Soliris enters Phase 3

A biosimilar can enter clinical trials, but not permitted for sale on the market until the Soliris patent expires.

11. Gene therapy cures blindness

Not all types of blindness.

15. ProQR transforms the CF landscape

That's a long shot, given that it's still in the pre-clinical research stage. It will be great if it works.
http://www.thestreet.com/story/12891378/1/biotech-stock-mailbag-proqr-vertex-pharma-tekmira-agios.html